A phase I safety, pharmacological, and biological study of the farnesyl protein transferase inhibitor, lonafarnib (SCH 663366), in combination with cisplatin and gemcitabine in patients with advanced solid tumors

被引：0
|
作者：
Laura Q. M. Chow
S. Gail Eckhardt
Cindy L. O’Bryant
Mary Kay Schultz
Mark Morrow
Stacy Grolnic
Michele Basche
Lia Gore
机构：
[1] University of Colorado Cancer Center,
[2] The Children’s Hospital,undefined
[3] University of Colorado Health Sciences Center at Fitzsimons,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2008年 / 62卷
关键词：
Lonafarnib; SCH66336; Cisplatin; Gemcitabine; Farnesyltransferase; Phase I; Pharmacokinetics;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：631 / 646
页数：15
相关论文
共 50 条
  • [31] Phase I Study Evaluating WEE1 Inhibitor AZD1775 As Monotherapy and in Combination With Gemcitabine, Cisplatin, or Carboplatin in Patients With Advanced Solid Tumors
    Leijen, Suzanne
    van Geel, Robin M. J. M.
    Pavlick, Anna C.
    Tibes, Raoul
    Rosen, Lee
    Razak, Albiruni R. Abdul
    Lam, Raymond
    Demuth, Tim
    Rose, Shelonitda
    Lee, Mark A.
    Freshwater, Tomoko
    Shumway, Stuart
    Liang, Li Wen
    Oza, Amit M.
    Schellens, Jan H. M.
    Shapiro, Geoffrey I.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (36) : 4371 - +
  • [32] A phase I study of Lonafarnib, a farnesyl transferase inhibitor in combination with herceptin plus paclitaxel in Her 2/neu overexpressing breast cancer
    Schellens, Jan H.
    Dieras, Veronique
    Roelvink, Marja
    Awada, Ahmad
    Govaerts, Anne-Sophie
    Bogaerts, Jan
    Marreaud, Sandrine
    Lacombe, Denis
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3470S - 3471S
  • [33] A Phase I Multicenter Study of Continuous Oral Administration of Lonafarnib (SCH 66336) and Intravenous Gemcitabine in Patients With Advanced Cancer
    Wong, Nan Soon
    Meadows, Kellen L.
    Rosen, Lee S.
    Adjei, Alex A.
    Kaufmann, Scott H.
    Morse, Michael A.
    Petros, William P.
    Zhu, Yali
    Statkevich, Paul
    Cutler, David L.
    Meyers, Michael L.
    Hurwitz, Herbert I.
    CANCER INVESTIGATION, 2011, 29 (09) : 617 - 625
  • [34] A phase I trial of lurbinectedin in combination with cisplatin in patients with advanced solid tumors
    Metaxas, Yannis
    Kahatt, Carmen
    Alfaro, Vicente
    Fudio, Salvador
    Zeaiter, Ali
    Plummer, Ruth
    Sessa, Cristiana
    Von Moos, Roger
    Forster, Martin
    Stathis, Anastasios
    INVESTIGATIONAL NEW DRUGS, 2022, 40 (01) : 91 - 98
  • [35] A phase I trial of lurbinectedin in combination with cisplatin in patients with advanced solid tumors
    Yannis Metaxas
    Carmen Kahatt
    Vicente Alfaro
    Salvador Fudio
    Ali Zeaiter
    Ruth Plummer
    Cristiana Sessa
    Roger Von Moos
    Martin Forster
    Anastasios Stathis
    Investigational New Drugs, 2022, 40 : 91 - 98
  • [36] Phase I study of piritrexim and gemcitabine in patients with advanced solid tumors
    Huie, M
    Carducci, M
    Liu, G
    Wilding, GG
    Marnocha, R
    Izquierda, M
    Thomas, J
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2005, 28 (06): : 613 - 617
  • [37] Phase I study on docetaxel and Gemcitabine in patients with advanced solid tumors
    Jaremtchuk, AV
    Zarba, JJ
    Ferro, A
    ANNALS OF ONCOLOGY, 1998, 9 : 138 - 139
  • [38] A phase I trial of elimusertib in combination with cisplatin or with cisplatin plus gemcitabine in advanced solid tumors with an emphasis on urothelial carcinoma
    Leibrandt, Ryan
    Frankel, Paul Henry
    Beumer, Jan Hendrik
    Takebe, Naoko
    Yin, Ming
    Emamekhoo, Hamid
    Lara, Primo Lucky N.
    Gore, Steven
    Parikh, Mamta
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [39] Phase IB study of sorafenib in combination with gemcitabine and cisplatin in patients with refractory solid tumors
    Schultheis, B.
    Kummer, G.
    Zeth, M.
    Brendel, E.
    Xia, C.
    Kornacker, M.
    Strumberg, D.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 69 (02) : 333 - 339
  • [40] Phase IB study of sorafenib in combination with gemcitabine and cisplatin in patients with refractory solid tumors
    B. Schultheis
    G. Kummer
    M. Zeth
    E. Brendel
    C. Xia
    M. Kornacker
    D. Strumberg
    Cancer Chemotherapy and Pharmacology, 2012, 69 : 333 - 339
12345